AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02829346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peri-articular tranexamic acid
Description: 750 mg of peri-articular TXA, prior to deflating the tourniquet and wound closure
Study NCT02829346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous tranexamic acid
Description: 750 mg of IV TXA, prior to deflating the tourniquet and wound closure
Study NCT01390701 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical nerve stimulation
Description: 30 min of bi-daily low-frequency transcutaneous electrical nerve stimulation on the upper extremities. Duration: 28+-4 days.
Study NCT01390701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: felodipin
Description: 2,5mg of felodipin once daily. Duration: 28+-4 days.
Study NCT00976768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin, 5-fluorouracil
Description: Oxaliplatin 85 mg/㎡ IV, day 1 over 2 hours 5-FU 400 mg/㎡ IV bolus day 1 followed by 5-fluorouracil(FU) 2,400 mg/㎡ and leucovorin (LV) 100 mg/㎡ IV continuous over 46 hours (every 2 weeks)
Study NCT02371733 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upper extremity aerobic exercise training
Description: Training group will receive upper extremity aerobic exercise training using arm ergometer at 50-80% of maximal heart rate and breathing exercises.~Training will exercise with arm ergometer 3days/week, for 6 weeks with the assistance of a physiotherapist. Training workload will be undercontrol both using target heart rate and Modified Borg dyspnea scale. Training group will also perform breathing exercises 120 times/day, 7 days/week, for 6 weeks.
Study NCT02371733 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Alternative upper extremity exercises
Description: Control group will receive alternative upper extremity exercises and breathing exercises. Control group will perform alternative upper extremity exercises 3days/week, for 6 weeks and also breathing exercises 120 times/day, 7 days/week, for 6 weeks.~Control group will be followed-up by telephone once a week.
Study NCT03743558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smartphone homemade video
Description: value of a video recording of the child sleep on smartphone made by the parents
Study NCT00841295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parenteral L-carnitine supplementation
Description: Parenteral carnitine supplementation (9 ± 1 mg/kg/d), from day 4, until than enteral nutrition provides sufficient carnitine source.
Study NCT00841295 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Parenteral supplementation with sterile water
Description: Parenteral supplementation with an equivalent volume of sterile water
Study NCT02629081 — intervention group
Intervention type: OTHER
Intervention: Controls & Cases
Description: All interventions are standard of care and both controls and cases will be treated the same. IEE results from controls and cases will be compared.
Study NCT01400334 — intervention group
Intervention type: RADIATION
Intervention: Positron Emission Tomography
Description: Quantification of cardiac function using positron emission tomography and: a)11C-meta-hydroxyephedrine \[HED, 20 mCi (740 MBq)\] to quantify sympathetic nerve function, b) 13N-ammonia \[NH3, 20 mCi (740 MBq)\] for regional perfusion, and c) 18F-2-deoxyglucose \[FDG; 6.5 mCi (241 MBq)\] administered during a hyperinsulinemic-euglycemic clamp to assess viability.
Study NCT00592358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliperidone
Description: tablet, 3mgQAM - 6mgQAM, taken daily for 8 weeks
Study NCT03843658 — intervention group
Intervention type: OTHER
Intervention: There is no intervention, but a diagnosis.
Description: Cohorts will be determined by the primary rheumatology diagnosis.
Study NCT01243606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single Diagnosis Treatment Protocol
Description: SDPs include: Managing Social Anxiety: A CBT Approach; Mastery of Anxiety and Panic-IV; Mastery of Anxiety and Worry-II; and Obsessive-Compulsive Disorder: A CBT Approach
Study NCT02495935 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OkuStim®
Description: Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany
Study NCT02495935 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-OkuStim®
Description: Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany
Study NCT01299532 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macrolane VRF30
Description: Device: Macrolane VRF30 (stabilized hyaluronic acid of non-animal origin) Treatment: Initial injection of a maximum of 120 ml/breast. Re-injection of a maximum of 120 ml/breast in a subgroup of subjects.
Study NCT02838706 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery for hip fracture
Study NCT01243606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP)
Description: The UP is designed to help patients learn how to confront and experience uncomfortable emotions and learn how to respond to their emotions in more adaptive ways. Individual treatment sessions will be conducted by experienced clinicians who will be trained in the administration of this protocol. A workbook will be provided to each patient as part of this manualized treatment. Treatment and session length of the UP will be matched to the SDPs for each principal diagnosis (see description above).
Study NCT00653796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe + Atorvastatin
Description: oral tablets: ezetimibe 10 mg + atorvastatin 10 mg once daily for 6 weeks
Study NCT00653796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: oral tablets: atorvastatin 10 mg + ezetimibe placebo once daily for 6 weeks
Study NCT00628511 — intervention group
Intervention type: DEVICE
Intervention: ARES (Apnea Risk Evaluation System)
Description: application of portable monitoring device with PSG
Study NCT03572543 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (Fpz, 10-20 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/out at the begging and end of the 20-minutes of stimulation over the course of 30 seconds.
Study NCT03572543 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (Fpz, 10-20 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/out at the begging and end of the 20-minutes of stimulation over the course of 30 seconds.
Study NCT00854529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: sub-conjunctival injection of 1.25mg Bevacizumab
Study NCT00854529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: sub-conjunctival injection of 1.25mg Bevacizumab
Study NCT00918528 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal urethrotomy
Study NCT00918528 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Internal urethrotomy
Study NCT00918528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C - local injection
Study NCT03888300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Chest Physiotherapy, physical exercises
Study NCT03238248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine Subcutaneous Injection or Intravenous Infusion
Description: 75 mg/m2
Study NCT03238248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat Infusion
Description: 20 mg/m2
Study NCT03238248 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy & Aspirate
Description: Removal of a small piece of bone and bone marrow by inserting a needle into hip bone.
Study NCT03616587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833
Description: Part A: AZD9833 monotherapy dose escalation.
Study NCT03616587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833
Description: Part B: AZD9833 monotherapy expansion.
Study NCT03616587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 with palbociclib
Description: Part C: AZD9833 in combination with palbociclib dose escalation
Study NCT03616587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 with palbociclib
Description: Part D: AZD9833 in combination with palbociclib expansion
Study NCT03616587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 with everolimus
Description: Part E: AZD9833 in combination with everolimus dose escalation
Study NCT03616587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 with everolimus
Description: Part F: AZD9833 in combination with everolimus dose expansion
Study NCT03616587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 with abemaciclib
Description: Part G: AZD9833 in combination with abemaciclib (± anastrozole) dose escalation
Study NCT03616587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 with abemaciclib
Description: Part H: AZD9833 in combination with abemaciclib (± anastrozole) dose expansion
Study NCT03616587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 with capivasertib
Description: Part I: AZD9833 in combination with capivasertib dose escalation
Study NCT03616587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 with capivasertib
Description: Part J: AZD9833 in combination with capivasertib dose expansion
Study NCT00289718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Twinrix™ adult
Description: Intramuscular administration
Study NCT01810965 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: First evaluation phase : no intervention / Second evaluation phase: bloodletting of 7 ml/kg (with a maximum of 500ml)
Study NCT01402895 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Transversus abdominus exercise
Study NCT01402895 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobilizations
Description: The physiotherapist will perform mobilizations to the L-spine and SI joints with the participant in a specific position.
Study NCT03265327 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral supplement containing omega-3 and omega-6
Description: An oral supplement containing omega-3 and omega-6
Study NCT03265327 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral supplement containing coconut and olive oil
Description: An oral supplement containing coconut oil and olive oil
Study NCT03447184 — intervention group
Intervention type: DRUG
Intervention: Androgen priming
Description: Androgen priming: with a low dose of recombinant hCG, aromatase inhibitor, and a depot GnRHa for 8 weeks Stimulation: a standard rFSH stimulation with either 300 IU rFSH or 300 IU (rFSH + rLH) Blood sampling: 6 blood samples to measure FSH, LH, E2, testosterone, and AMH Ultrasound examination: to count all antral follicles, 2-10 mm in each ovary Follicular fluid: to analyze E2, androstenedione, testosterone, progesterone, inhibin B.~Granulosa cells: to analyze gene expression in cumulus and mural granulosa cells of Luteinising hormone receptor (LHR), 3β-hydroxy-steroid-dehydrogenase (3ßHSD), inhibin-Ba (INHB-A) receptor, androgen and FSH receptor
Study NCT01955980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Inhalation
Study NCT01955980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Nasal Spray
Study NCT00880685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: 10-30mg, daily for 8 weeks
Study NCT04300621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTF 1
Description: Participants will receive (S)-ketamine administered sublingually through OTF 1.
Study NCT04300621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTF 2
Description: Participants will receive (S)-ketamine administered sublingually through OTF 2.
Study NCT04300621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTF 3
Description: Participants will receive (S)-ketamine administered sublingually through OTF 3.
Study NCT02218398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Study NCT01499043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: Capsules administered twice daily, continuous dosing. Subjects will take PLX3397 at 1000 mg/day.
Study NCT03185741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UMS Strategy
Description: Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.
Study NCT03185741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Text Messaging
Description: Patients will receive daily text message reminders about when to take medicines based on UMS intervals.
Study NCT03370510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin nasal spray.
Study NCT03370510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pivotal Response Treatment
Description: An evidence-based manualized treatment for individuals with autism, which was specifically designed to improve social communication.
Study NCT03370510 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Pivotal Response Treatment
Description: An evidence-based manualized treatment for individuals with autism, which was specifically designed to improve social communication.
Study NCT03370510 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray.
Study NCT02341690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval walking training
Description: Interval Walking Training with the InterWalk Application An Interval-walking bout will consist of repeated cycles of 3 minutes of fast and 3 minutes of slow walking at 70% and 40% of the smart-phone assessed peak VO2-rate, respectively.~IWT is conducted for at least 60 minutes per day, three days per week. Compliance is monitored continuously using the on-board accelerometer logger
Study NCT02691494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Film-coated tablets
Study NCT02691494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Estradiol/Norethindrone Acetate
Description: Placebo capsules
Study NCT04575805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Bias Modification-Attention (iCBM-A)
Description: The iCBM-A is online CBM intervention for obsessive-compulsive symptoms comprised of delivery of the modified dot-probe task taking place over eight sessions, twice per week for 4 weeks.
Study NCT02050789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: flexible duty hours
Description: If a hospital is assigned to the intervention arm, all categorical and preliminary general surgery residents in that general surgery program will switch to the flexible duty hours while at an enrolled hospital.
Study NCT03951376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UPRIGHT intervention
Description: The UPRIGHT intervention design consists of two different phases consecutively implemented in two school years: intensive phase and follow-up phase. During the intensive phase, all stakeholders are trained in the UPRIGHT WELL-BEING FOR US programme (18 skills). The follow-up phase (WELL-BEING FOR ALL) intends not only to maintain the effect of the intensive training in youths, but also to boost the positive mental health atmosphere created in the whole school. To do so, different collective activities will be organized at school level such as celebration of thematic days, activities with the community, and outdoor/indoor activities.
Study NCT04300621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTF 4
Description: Participants will receive (S)-ketamine administered sublingually through OTF 4.
Study NCT02341690 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: Standard care at the promotion centre in the municipality
Study NCT00646984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard continuous antiretroviral therapy
Study NCT00646984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD-4 guided therapy interruption
Description: Stop antiretroviral therapy when CD-4 equal or above 350 and reinitiate when below 350
Study NCT00646984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viral load driven treatment interruption
Description: Stop antiretroviral therapy when viral load below 30,000 copies/ml and reinitiate when equal or above 30,000 copies/ml
Study NCT03515044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg Rifaximin SSD once daily
Description: SSD once daily (QD)
Study NCT03515044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg Rifaximin SSD twice daily
Description: SSD twice daily (BID)
Study NCT03515044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 mg Rifaximin SSD once daily
Description: SSD once daily (QD)
Study NCT03515044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 mg Rifaximin SSD twice daily
Description: SSD twice daily (BID)
Study NCT03515044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered twice daily (BID)
Study NCT03332433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula oxygenation
Description: Oxygen is supplied with a high-flow nasal cannula oxygenation device，the flow is up to 60L/min
Study NCT04348422 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 RT-PCR
Description: Nasoropharyngeal swabs for COVID-19 RT-PCR - initial screening/retest +every 10 days in 100 days followup period
Study NCT04348422 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 Serology
Description: Blood samples for COVID-19 serology - initial screening/retest +every 10 days in 100 days followup period Each sample will be examined by 4-6 serology kits.
Study NCT04348422 — intervention group
Intervention type: OTHER
Intervention: Symptoms questionnare
Description: Symptoms questionnaire which will be filled by participant on initial screening/retest visit + every 10 days in 100 days followup period
Study NCT01624233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab
Description: Administered SC
Study NCT02364258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
Study NCT02364258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
Study NCT03573336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: Intake orally, once daily
Study NCT03573336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Intake orally, once daily
Study NCT03382041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon Fiber Implant
Description: A cannulated rod, made of long carbon fiber reinforced polymer, with interlocking holes at its proximal and distal ends. The Nail provides for a slight bend. A Tantalum radiopaque marker along the Nail longitudinal axis provides for its visualization under fluoroscopy. The Nail proximal end is marked by a tantalum marker.
Study NCT03382041 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium Implant
Description: An intramedullary rod, also known as an intramedullary nail (IM nail) or inter-locking nail or Küntscher nail (without proximal or distal fixation), is a metal rod forced into the medullary cavity of a bone. IM nails have long been used to treat fractures of long bones of the body
Study NCT02691676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasmalyte
Description: Parenteral administration of Plasmalyte initiated immediately after collection of the first blood sample at 166 mL/hour. Thus, all patients received 1000 mL of infusion solution over 6 hours.
Study NCT02691676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringerfundin
Description: Parenteral administration of Ringerfundin initiated immediately after collection of the first blood sample at 166 mL/hour. Thus, all patients received 1000 mL of infusion solution over 6 hours.
Study NCT03590119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lutetium Lu 177-DOTATATE
Description: Intra-arterial infusion of Lu-177-DOTATATE
Study NCT03590119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177-DOTATATE
Description: Intra-arterial infusion of Lu-177-DOTATATE
Study NCT03113227 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal ultrasound
Description: Transvaginal ultrasound will be made for assessment of posterior cervical angle and cervical length